<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104278">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02008461</url>
  </required_header>
  <id_info>
    <org_study_id>BT_SVT</org_study_id>
    <nct_id>NCT02008461</nct_id>
  </id_info>
  <brief_title>Botulinum Toxin Injection for Preventing Secondary Atrial Fibrillation in Patient With Supra-ventricular Tachyarrythmias</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meshalkin Research Institute of Pathology of Circulation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meshalkin Research Institute of Pathology of Circulation</source>
  <oversight_info>
    <authority>Russia: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators have conducted a prospective, double-blind, randomized study to assess the
      comparative safety and efficacy of two different ablation strategies, RFA versus RFA plus
      botulinum toxin injection, in patients with supra-ventricular tachyarrhythmias. Results were
      assessed with the use of an implanted monitoring device (IMD).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>number of episodes of atrial fibrillation</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>serious adverse events</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Supra-ventricular Tachyarrhythmias</condition>
  <arm_group>
    <arm_group_label>RFA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mapping and radiofrequency ablation are performed by using standard methods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RFA+BT injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mapping and radiofrequency ablation are performed by using standard methods.
Injection of the botulinum toxin is performed in main anatomical zones of ganglionated plexuses of left atrium using Myostar catheter (Biosense Webster).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radiofrequency ablation</intervention_name>
    <arm_group_label>RFA</arm_group_label>
    <arm_group_label>RFA+BT injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>botulinum toxin injection</intervention_name>
    <arm_group_label>RFA+BT injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  atrial flutter, AV nodal re-entry tachycardia, focal atrial tachycardia, WPW syndrome

          -  secondary atrial fibrillation

        Exclusion Criteria:

          -  congestive heart failure

          -  LV ejection fraction &lt; 35%

          -  left atrial diameter &gt; 60 mm
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Evgeny Pokushalov, MD, PhD</last_name>
    <phone>+79139254858</phone>
    <email>e.pokushalov@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Valley Health System and Columbia University College of Physicians &amp; Surgeons</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11528</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan S. Steinberg</last_name>
      <email>jss7@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan S. Steinberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>State Research Institute of Circulation Pathology</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630055</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evgeny Pokushalov, MD, PhD</last_name>
      <phone>+79139254858</phone>
      <email>E.Pokushalov@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Evgeny Pokushalov, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>http://meshalkin.ru</url>
    <description>State Research Institute of Circulation Pathology Official Site</description>
  </link>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 6, 2013</lastchanged_date>
  <firstreceived_date>December 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
